Evidence map›Paper›PMID 28008156›Full record

ArticleOncotarget2017

Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.

Yanxiao Zhang, Jingcheng Yu, Vladimir Grachtchouk, Tingting Qin, Carey N Lumeng, Maureen A Sartor, Ronald J Koenig

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Coding Molecular Determinants of Thyroid Cancer Development and Progression.Endocrinology and metabolism clinics of North America · 2019
    Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yanxiao ZhangDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Jingcheng YuDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Vladimir GrachtchoukDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Tingting QinDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Carey N LumengDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI 48109, USA.
Maureen A SartorDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Ronald J KoenigDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
University of Michigan–Ann Arbor · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Regulation of Adipose Tissue Inflammation By Antigen Presenting CellsR01DK090262 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, CAREY N · 2011 to 2024
$5.3M
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancerR01CA166033 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOENIG, RONALD JAY · 2013 to 2017
$2.4M
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancerR01CA151842 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOENIG, RONALD JAY · 2010 to 2014
$1.6M
NCI NIH HHS R01 CA151842NCI NIH HHS R01 CA166033NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK090262
6 · The paper itself

Abstract

PAX8-PPARG fusion protein (PPFP) results from a t(2;3)(q13;p25) chromosomal translocation, is found in 30% of follicular thyroid carcinomas, and demonstrates oncogenic capacity in transgenic mice. A PPARG ligand, pioglitazone, is highly therapeutic in mice with PPFP thyroid cancer. However, only limited data exist to characterize the binding sites and oncogenic function of PPFP, or to explain the observed therapeutic effect of pioglitazone. Here we used our previously characterized transgenic mouse model of PPFP follicular thyroid carcinoma to identify PPFP binding sites in vivo using ChIP-seq, and to distinguish genes and pathways regulated directly or indirectly by PPFP with and without pioglitazone treatment via integration with RNA-seq data. PPFP bound to DNA regions containing the PAX8 and/or the PPARG motif, near genes involved in lipid metabolism, the cell cycle, apoptosis, and cell motility; the binding site distribution was highly concordant with our previous study in a rat PCCL3 cell line. Most strikingly, pioglitazone induced an immune cell infiltration including macrophages and T cells only in the presence of PPFP, which may be central to its therapeutic effect.

Indexed as

Gene Regulatory NetworksAdenocarcinoma, FollicularAnimalsBinding SitesChromatin ImmunoprecipitationDisease Models, AnimalGene Expression Regulation, NeoplasticHumansMiceMice, TransgenicPAX8 Transcription FactorPioglitazonePPAR gammaRatsRecombinant Fusion ProteinsSequence Analysis, DNAPAX8 protein, humanPAX8 Transcription FactorPioglitazonePPAR gammaRecombinant Fusion ProteinsThiazolidinedionesdifferentiationfollicular thyroid cancergene fusionperoxisome proliferator-activated receptor gammapioglitazone

Identifiers

PMID28008156
PMCPMC5351587
OpenAlexW2567691285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.